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Background: As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify
more accurate prognostic markers for the disease. There is some evidence that a higher modified Glasgow
Prognostic Score (mGPS) may be associated with poorer survival in patients with prostate cancer but it is not
known whether this is independent of other established prognostic factors. Therefore the aim of this study was to
describe the relationship between mGPS and survival in patients with prostate cancer after adjustment for other
prognostic factors.
Methods: Retrospective clinical series on patients in Glasgow, Scotland, for whom data from the Scottish Cancer
Registry, including Gleason score, Prostate Specific Antigen (PSA), C-reactive protein (CRP) and albumin, six months
prior to or following the diagnosis, were included in this study.
The mGPS was constructed by combining CRP and albumin. Five-year and ten-year relative survival and relative
excess risk of death were estimated by mGPS categories after adjusting for age, socioeconomic circumstances,
Gleason score, PSA and previous in-patient bed days.
Results: Seven hundred and forty four prostate cancer patients were identified; of these, 497 (66.8%) died during a
maximum follow up of 11.9 years. Patients with mGPS of 2 had poorest 5-year and 10-year relative survival, of
32.6% and 18.8%, respectively. Raised mGPS also had a significant association with excess risk of death at five years
(mGPS 2: Relative Excess Risk = 3.57, 95% CI 2.31-5.52) and ten years (mGPS 2: Relative Excess Risk = 3.42, 95% CI
2.25-5.21) after adjusting for age, socioeconomic circumstances, Gleason score, PSA and previous in-patient bed
days.
Conclusions: The mGPS is an independent and objective prognostic indicator for survival of patients with prostate
cancer. It may be useful in determining the clinical management of patients with prostate cancer in addition to
established prognostic markers.
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Survival in patients with prostate cancer has improved
in recent years but prognosis remains poorly under-
stood. It is often difficult to differentiate high risk pa-
tients who require potentially curative treatment from
low risk patients for whom watchful waiting is sufficient.
There is also increasing evidence that radical prostatec-
tomy, with its high iatrogenic morbidity, confers no ap-
preciable survival benefit to watchful waiting in localized
disease [1]. Considerable effort has gone into identifying
novel genetic and immunological biomarkers for pros-
tate cancer outcomes. However, these remain time con-
suming and not validated within routine clinical practice
[2,3]. Currently, imprecise clinical prognostication is based
on readily available tumour related factors, including Pros-
tate Specific Antigen (PSA) levels, Gleason score, surgical
margins and pathological stage [4].
There is increasing recognition that systemic inflam-
mation is associated with progression and reduced sur-
vival of prostate cancer patients [5,6]. In particular, the
systemic inflammatory response, as evidenced by an ele-
vated C-reactive protein (CRP), has been shown to be in-
dependently associated with poor prognosis in localised
and metastatic prostate cancer [7]. For example, in a retro-
spective study of 160 patients from the ASCENT (Andro-
gen- Independent Prostate Cancer Study of Calcitriol
Enhancing Taxotere) trial, CRP levels appeared to be a
predictor of poorer survival [8]. This finding was also
shown in another independent dataset of 119 patients with
castration-resistant prostate cancer (of whom 57 received
docetaxel) enrolled in six phase II clinical trials [9]. These
initial findings are limited, however, by the relatively small
number of cases and prognostic factors that were consid-
ered and adjusted for in the multivariate analysis. Earlier
studies on systemic inflammation and prostate cancer sur-
vival had smaller sample sizes and follow-up was also lim-
ited from 12 to 24 months following diagnosis. In a recent
review it has been concluded that CRP might serve as a
useful biomarker for urological cancers and that it satisfies
the 2001 NIH criteria to be used as a biomarker [10].
More recently, systemic inflammation based prognos-
tic scores such as the modified Glasgow Prognostic
Score (mGPS, a combination of C-reactive protein and
albumin), have been developed [7] and found to have
significant prognostic value in one-year and five-year
survival from prostate cancer [11]. However, thes find-
ings from the Glasgow Inflammation Outcome Study
(GIOS), failed to account for PSA and comorbidities that
would be known to clinicians at the time of diagnosis.
Furthermore, earlier study could not examine the rela-
tionship between mGPS and long term survival. There-
fore the aim of this study was to examine in greater
detail the associations between the mGPS and survival
in a large mature cohort of patients with prostate cancerand to establish whether it had prognostic significance
independent of PSA and comorbidities.
Methods
Data of prostate cancer patients diagnosed between 2000
and 2006, from the Scottish Cancer Registry, (Scottish
Morbidity Record number six (SMR06)) were obtained.
Prostate cancer was defined as International Classifica-
tion of Diseases (ICD), revision 10 code C61. We identi-
fied prostate cancer patients in the North Glasgow
biochemistry database by extracting records of all pa-
tients for whom PSA had been requested. We linked
Cancer Registry records to routine biochemistry labora-
tory records using an indexing method that ensured that
patient identifiers and clinical information were never
transferred in the same dataset. The linkage was carried
out by exact matching of patients’ forename, surname
and date of birth, followed by a Soundex phonetic
matching algorithm if initial exact matching was unsuc-
cessful. Only data for those patients who had a blood
sample taken within a period of six months before or six
months after the diagnosis of prostate cancer were in-
cluded. Out of 8,483 prostate cancer patients diagnosed
in the West of Scotland region from 1st January 2000 to
31st December 2006, PSA data were available for 1,861
patients in Glasgow. Of these, patients whose data for
C-reactive protein and albumin were available were in-
cluded in this study. If more than one record was avail-
able for a patient within a six month period (before or
after diagnosis) then only the record close to the date of
diagnosis was used.
The Gleason grading system is known to be associated
with prostatic cancer prognosis [12] and was used to de-
scribe tumour morphology. Gleason score was extracted
from the Scottish Cancer Registry, where available. The
information on Gleason score was obtained through
prostatic biopsy. The number of hospital in-patient bed
days in the period of 10 years up to 1 year preceding
diagnosis of prostate cancer were also obtained and used
as a crude measure of general pre-existing co-morbidity.
In-patient bed days have been previously used as meas-
ure of co-morbidity in patients with breast and colorec-
tal cancer in Scotland [13]. Date and cause of death was
extracted through cancer registration patient based link-
age with National Records of Scotland death records.
Socio-economic status of individuals was assigned by
matching their postcode of residence at diagnosis to the
Scottish Index of Multiple Deprivation (SIMD) 2006 score.
SIMD is an area-based measure of socio-economic cir-
cumstances that ranks small geographic areas of Scotland
(datazones) from 1 (most deprived) to 6505 (least de-
prived) using 31 indicators that cover current income, em-
ployment, health, education, housing and access [14]. The
datazones are further grouped into national quintiles that
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fied Glasgow Prognostic score was constructed as de-
scribed in Table 1 [15]. This study was approved by the
West of Scotland Research Ethics Service (WoSRES refer-
ence number 11/AL0249).
Statistical analysis
Follow up was from date of incidence of cancer to the
date of death or censor date (31st December 2011),
whichever came first. Relative survival was used as a
measure of cancer patients’ survival. Relative survival
has a key advantage over the cause specific survival as it
does not rely on the accurate classification of cause of
death; instead it provides a measure of total prostate
cancer associated excess mortality.
Five and ten year relative survival estimates were made
by using age and deprivation specific life tables provided
by National Records of Scotland (formerly the General
Register Office). These were available until 2009 so for
the purposes of this study, the 2009 mortality rates were
used for both 2010 and 2011. Relative survival estimates
were made by age, deprivation, Gleason score and
mGPS, PSA and previous in-patient bed days using the
complete and hybrid approach (by STREL and STRS
commands in STATA) [16]. The STRS command in
STATA implements the Ederer II method by default for
the estimation of relative survival; however, we repeated
the analyses using both the Ederer I and Hakulinen ap-
proaches. All three methods provided identical results,
so the results presented in this study are based on the
Ederer II Method. Using Poisson regression modelling,
the relative excess risk was estimated after adjusting for
age, deprivation and Gleason score, PSA and previous
in-patient bed days [16]. The lowest category was used
as referent for the mGPS and all other categorical covar-
iates. All analyses were conducted using STATA version
11 (StataCorp, College Station, TX, USA). Adherence to
the proportional hazards assumption was investigated by
plotting smoothed Schoenfeld residuals against time; no
violations of the assumption were identified. All statis-
tical tests were two tailed and statistical significance was
taken as p < 0.05.
Results
A total of 744 patients who had a diagnosis of prostate
cancer, and had biochemistry data within six monthsTable 1 The modified Glasgow prognostic score
Prognostic score Score
The modified Glasgow prognostic score
C-reactive protein≤ 10 mg/l 0
C-reactive protein > 10 mg/l and albumin≥ 35 g/l 1
C-reactive protein > 10 mg/l and albumin < 35 g/l 2before or after diagnosis, were included in this study.
The majority of patients, 578 (78%), were aged 65 or
over. Thirty five percent of patients (n = 262) had high
Gleason score (Gleason 8–10), 21.9% had Gleason score
missing (n = 163) and nearly half of the cohort (n = 362,
49%) had PSA greater than 20ug/l. More than a third
of patients (n = 272, 37%) lived in the most socio-
economically deprived areas while only 18% lived in the
most affluent areas. The median follow-up from the can-
cer diagnosis was 4.11 years, and maximum 11.9 years.
Patients with an elevated mGPS (mGPS 1 and 2) were
significantly more likely to be 75 years or older (p = 0.014)
and have either high Gleason score disease (Gleason 8–
10) or unknown Gleason (p < 0.001) but there was no as-
sociation with socioeconomic circumstances based on
SIMD (p = 0.219) – Table 2. Patients with an elevated
mGPS were significantly more likely to have raised PSA
(PSA > 20 ug/l) and less likely to have higher previous in-
patients bed days (p-value 0.022).
Increasing age, Gleason score, PSA and previous in-
patient bed days were associated with poorer 5 and 10 year
relative survival (Table 3). Decreasing deprivation was as-
sociated with better 5 and 10 year relative survival. On
multivariate analysis, increasing age, Gleason score, PSA >
20 ug/l, previous inpatients bed days >28 and mGPS were
the major predictors of relative excess risk of death at 5
and 10 years (Table 3). Compared with patients with an
mGPS of 0, patients with an mGPS of 1 and 2 had higher
risks of death in the five years following diagnosis (RER
1.84, 95% CI 1.33-2.55, p <0.001 and RER 3.57, 2.31-5.25,
p < 0.001, respectively) which was independent of age,
Gleason score, SIMD, PSA and previous inpatient bed
days. Similarly, 10 year mortality was raised in patients
with mGPS of 1 and 2 (RER 1.87. 95% 1.37-2.55, p <0.001
and RER 3.42, 95% 2.25-5.21, p < 0.001, respectively) after
adjusting for other factors (Table 3).
When the analysis was stratified based on Gleason
score and PSA level, we observed a significant associ-
ation between mGPS and risk of death within ten
years of diagnosis with PSA < 10 ug/l group (RER 9.65,
95% CI 3.13-29.75, p for trend <0.001), PSA 10-20ug/l
category (RER 2.50, 95% CI 0.20-31.07, p for trend
0.088) and those with PSA > 20 ug/l (RER 5.01, 95% CI
3.05-8.22, p for trend 0.001) after adjustment for age,
socioeconomic circumstances and previous inpatient
bed days (Table 4). In grade-specific analysis, we ob-
served a significant association between the mGPS
and risk of death within 10 years at all grades of dis-
ease: low grade (RER 20.46, 95% CI 3.43-121.97, p for
trend <0.001), intermediate grade (RER 2.25, 95% CI
0.31-16.08, p for trend 0.003), high grade (RER 1.88,
95% CI0.98-3.61, p for trend 0.035) and unknown
grade (RER 1.97, 95% CI 1.03-3.73) after adjustment
for other factors (Table 4).
Table 2 Baseline characteristics of patients with prostate cancer based on mGPS categories
The modified Glasgow prognostic score (mGPS)
P-valuemGPS = 0 mGPS = 1 mGPS = 2
Patients, n (%) Patients, n (%) Patients, n (%)
Age at incidence (years)
Age < 65 88 (25.29) 71 (21.78) 7 (10.00)
0.014Age 65-74 127 (36.49) 112 (34.36) 22 (31.43)
Age≥ 75 133 (38.22) 143 (43.87) 41 (58.57)
Gleason score
Gleason < 7 95 (27.30) 67 (20.55) 15 (21.43)
<0.001
Gleason = 7 85 (24.43) 51 (15.64) 6 (8.57)
Gleason 8-10 124 (35.63) 113 (34.66) 25 (35.71)
Unknown Gleason 44 (12.64) 95 (29.14) 24 (34.29)
SIMD 2006, Quintiles
1 (most deprived) 117 (33.62) 128 (39.26) 27 (38.57)
0.219
2 71 (20.40) 70 (21.47) 9 (12.86)
3 46 (13.22) 45 (13.80) 9 (12.86)
4 43 (12.36) 28 (8.59) 13 (18.57)
5 (least deprived) 71 (20.40) 55 (16.87) 12 (17.14)
Prostate specific antigen (ug/l)
PSA < 10 140 (40.35) 99 (30.46) 26 (37.14)
<0.001PSA 10-20 69 (19.88) 42 (12.92) 4 (5.71)
PSA > 20 138 (39.77) 184 (56.62) 40 (57.14)
Previous inpatient bed days
0 200 (57.47) 174 (53.37) 30 (42.86)
0.022
1-7 73 (20.98) 65 (19.94) 17 (24.29)
8-28 55 (15.80) 64 (19.63) 11 (15.71)
29+ 20 (5.75) 23 (7.06) 12 (17.14)
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diagnosis (n = 149) to minimise the effects of “reverse
causality”, elevated mGPS showed an increased risk of
death at five (RER 2.43, 95% CI 1.23-4.79, p-value 0.011)
and ten years (RER 2.42, 95% CI 1.29-4.58, p-value
0.006) after adjusting for age, Gleason score, socio-
economic circumstances, PSA and inpatient bed days
(Table 5).
Figure 1 shows the age-specific relative survival of pros-
tate cancer patients based on the mGPS categories. Raised
level of mGPS (1 and 2), showed significantly poorer sur-
vival in all age groups with particularly worse survival in
the oldest group (age ≥ 75). There was no convincing dif-
ference in mortality between patients with mGPS scores
of 1 and 2 in patients under 75 years of age.
Discussion
The results of the present study indicate that a raised
level of mGPS is associated with poorer short and long
term survival in men with prostate cancer. Thisrelationship was independent of age at diagnosis, socio-
economic circumstances, Gleason score, PSA level and
previous in-patient bed days. These findings are consist-
ent with earlier observations from the Glasgow Inflam-
mation Outcome Study, where the mGPS was compared
with Neutrophil Lymphocyte Ratio and demonstrated
significant prognostic value [11]. The prognostic value
of mGPS remained consistent even after excluding
deaths in the first 12 months after diagnosis, which sug-
gest that disease stage is unlikely to explain the survival
differences between mGPS categories.
We observed 40% and 22% lower 5-year and 10-year
relative survival respectively, among those with raised
modified Glasgow Prognostic Score (mGPS = 2) com-
pared to the normal (mGPS = 0) following diagnosis of
prostate cancer. In the present study, patients with
raised mGPS were significantly more likely to have un-
known Gleason score and less likely to have low grade
disease compared with the mGPS of 0. Similarly, pa-
tients with raised mGPS (mGPS = 2) were significantly
Table 3 The relationship between patient characteristics and five and ten year relative survival and relative excess risk
of death of patients with prostate cancer
Five year survival and excess risk of death
P-value











0 74.8 (67.9-81.3) 1 51.4 (42.8-60.1) 1
1 48.3 (41.1-55.1) 1.84 (1.33-2.55) <0.001 22.4 (16.6-29.1) 1.87 (1.37-2.55) <0.001
2 32.6 (19.8-47.3) 3.57 (2.31-5.52) <0.001 18.8 (7.6-36.1) 3.42 (2.25-5.21) <0.001
Age at incidence (years)
Age < 65 73.3 (65.1-80.2) 1 47.4 (37.6-56.9) 1
Age 65-74 58.4 (50.9-65.6) 1.69 (1.15-2.49) 0.008 36.1 (28.3-44.3) 1.49 (1.05-2.12) 0.026
Age≥ 75 51.6 (43.2-60.3) 1.92 (1.31-2.80) 0.001 24.4 (16.8-33.7) 1.69 (1.20-2.40) 0.003
Gleason score
Gleason < 7 96.6 (87.6-100) 1 68.9 (56.1-81.1) 1
Gleason = 7 77.0 (66.4-86.2) 2.96 (1.19-7.37) 0.020 44.3 (32.5-56.5) 2.74 (1.28-5.86) 0.010
Gleason 8-10 50.0 (42.2-58.0) 7.18 (3.12-16.50) <0.001 25.1 (17.9-33.3) 5.55 (2.75-11.20) <0.001
Unknown Gleason 16.3 (10.4-23.7) 16.27 (7.09-37.34) <0.001 7.5 (3.2-14.7) 12.44 (6.12-25.29) <0.001
SIMD 2006, Quintiles
1 (most deprived) 49.9 (42.8-56.9) 1 27.8 (20.9-35.5) 1
2 51.0 (40.9-61.1) 1.24 (0.88-1.73) 0.221 25.4 (16.5-36.0) 1.28 (0.92-1.78) 0.146
3 70.4 (56.6-82.9) 0.80 (0.49-1.30) 0.364 35.2 (22.4-49.9) 0.91 (0.58-1.42) 0.682
4 74.4 (59.2-87.9) 0.81 (0.48-1.36) 0.419 49.0 (32.1-67.3) 0.93 (0.58-1.49) 0.761
5 (least deprived) 71.9 (59.4-83.6) 0.80 (0.51-1.24) 0.312 58.7 (42.2-76.2) 0.81 (0.53-1.23) 0.319
Prostate specific antigen
(ug/l)
PSA < 10 78.0 (70.4-84.8) 1 58.2 (48.4-67.9) 1
PSA 10-20 73.1 (60.6-84.2) 0.78 (0.44-1.38) 0.396 45.4 (31.4-60.3) 0.78 (0.44-1.39) 0.409
PSA > 20 40.4 (34.0-47.0) 1.47 (1.01-2.14) 0.041 15.4 (10.7-21.2) 1.82 (1.26-2.63) 0.002
Previous inpatient bed days
0 60.8 (54.5-66.9) 1 36.7 (30.3-44.0)
1-7 70.0 (59.2-79.9) 0.78 (0.53-1.15) 0.205 41.5 (29.7-54.2) 0.75 (0.51-1.09) 0.141
8-28 52.7 (41.3-64.0) 1.07 (0.74-1.55) 0.708 26.3 (16.2-38.7) 1.12 (0.79-1.59) 0.530
29+ 33.7 (19.7-49.5) 1.65 (1.09-2.51) 0.018 19.2 (7.1-38.6) 1.64 (1.08-2.47) 0.019
*Multivariate model included all the co-variates presented in the table.
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cific analysis, a raised mGPS had significant associations
with excess risk of death among patients regardless of
disease grading. The largest effect of mGPS was seen in
patients with low grade prostate cancer (Gleason < 7), i.
e. men with raised mGPS (mGPS = 2) were 46 and 20
times more likely to die in the first five and ten years fol-
lowing diagnosis compared to patients with a mGPS of
0. The large effect and wide confidence interval in this
category may be due to the small number of cases with
low Gleason score and raised mGPS (n = 15), of whom
11 died during ten years follow up.In PSA specific analysis, patients with raised mGPS
were significantly more likely to die in five and ten years
in both, PSA < 10ug/l and PSA > 20ug/l categories. Al-
though there was no significant association between
mGPS and survival in the intermediate PSA category
(PSA 10-20ug/l), this could have been due to the small
number of cases in intermediate PSA category with
raised mGPS (n = 4).
In the present study, patients with raised mGPS had
poorer five and ten year survival even when the deaths
in the first 12 months were excluded from the analysis.
This was based on the assumption that patients with
Table 4 Relative excess risk of death of prostate cancer patients based on Gleason score and PSA categories
Modified Glasgow prognostic score P-value
for trend0 1 2
Gleason score-specific analysis
Gleason < 7
Relative excess risk (95% CI)a reference 1.66 (0.15-18.65) 46.04 (4.59-461.70) 0.013
Relative excess risk (95% CI)b reference 3.26 (0.67-15.89) 20.46 (3.43-121.97) 0.002
Gleason = 7
Relative excess risk (95% CI)a reference 3.06 (1.28-7.35) 2.19 (0.25-19.20) 0.021
Relative excess risk (95% CI)b reference 3.99 (1.78-8.97) 2.25 (0.31-16.08) 0.003
Gleason 8-10
Relative excess risk (95% CI)a reference 2.09 (1.29-3.37) 5.27 (2.73-10.22) <0.001
Relative excess risk (95% CI)b reference 2.04 (1.30-3.22) 5.64 (3.00-10.59) <0.001
Unknown Gleason
Relative excess risk (95% CI)a reference 1.55 (0.98-2.46) 2.18 (1.13-4.22) 0.015
Relative excess risk (95% CI)b reference 1.51 (0.96-2.37) 1.88 (0.98-3.61) 0.035
PSA-specific analysis
PSA < 10ug/l
Relative excess risk (95% CI)a reference 3.43 (1.37-8.59) 8.29 (2.76-24.87) <0.001
Relative excess risk (95% CI)b reference 3.86 (1.48-10.03) 9.65 (3.13-29.75) <0.001
PSA 10-20ug/l
Relative excess risk (95% CI)a reference 1.87 (0.63-5.58) 3.65 (0.47-28.49) 0.163
Relative excess risk (95% CI)b reference 2.54 (0.90-7.18) 2.50 (0.20-31.07) 0.088
PSA > 20ug/l
Relative excess risk (95% CI)a reference 2.20 (1.50-3.24) 5.08 (3.03-8.55) <0.001
Relative excess risk (95% CI)b reference 2.25 (1.57-3.20) 5.01 (3.05-8.22) <0.001
All estimates were presented after adjusted for age, deprivation and inpatient bed days. a = five-year relative survival, b = 10-year relative survival.
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markers and the overall effect of mGPS may be driven
by the advance stage disease among men with the raised
mGPS. Exclusion of early deaths from analysis did not
change the prognostic value of the mGPS, this suggest
that differential distribution of metastatic disease be-
tween mGPS categories is unlikely to explain the prog-
nostic significance of mGPS. Furthermore, previousTable 5 Five and ten year conditional relative survival and re







0 83.0 (75.8-89.5) 1
1 64.1 (55.7-72.0) 1.66 (1.12-2.46)
2 56.9 (35.6-77.3) 2.43 (1.23-4.79)
Estimates adjusted for age, Gleason score, socioeconomic circumstances, PSA and i
in first 12 months following the diagnosis.studies have shown systemic inflammation to be associ-
ated with survival, independent of disease stage, for gas-
troesophageal, colorectal (including those with liver
metastases), renal, breast and prostate cancers [17-19]
however, the findings of earlier prostate cancer study are
based on smaller sample (n = 62) [17].
Additionally, the raised mGPS (1 and 2) has shown
poorer survival in all age groups. This is of particularlative excess risk of death of prostate cancer patients
h
P-value






0.012 43.2 (32.0-55.5) 1.75 (1.21-2.53) 0.003
0.011 38.8 (16.6-67.0) 2.42 (1.29-4.58) 0.006
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Figure 1 The modified Glasgow prognostic score and survival based on age categorie.
Shafique et al. BMC Cancer 2013, 13:292 Page 7 of 8
http://www.biomedcentral.com/1471-2407/13/292interest in the younger age group (<65 years) where
most uncertainty lies about the management of disease
and treatment decisions are made on the basis of indi-
vidual’s age, fitness, comorbidity, PSA, Gleason score
and disease stage. Novel genetic and immunological bio-
markers have been identified but these, to date, have not
been incorporated into routine clinical practice [2,3].
The results of the present study further strengthen the
earlier observations that systemic inflammation is of
clinical importance and suggest the routine use of the
mGPS may be a cost effective, readily available tool for
risk stratification in patients with prostate cancer.
Strengths of our study include its large sample size, in-
clusion of information on PSA and Gleason score and a
fairly long follow-up to determine the effect of systemic
inflammation on short and long term survival. However,
our study has limitations. First, patients were selected on
the basis of availability of PSA, C-reactive protein and
albumin, therefore this cohort of patients might not be
representative of all the prostate cancer patients diag-
nosed and treated in the area. Second, the reason whythese patients were tested for C-reactive protein remains
unclear and there is a possibility that they might have
had concurrent morbidity for which they were clinically
investigated. However, this is unlikely to have had a
major effect on our results, as we adjusted for back-
ground mortality as well as the previous inpatient bed
days from ten years to one year prior to the diagnosis of
prostate cancer. The value of mGPS between different
treatment groups need to be evalued in future work and
further work is also required to investigate this relation-
ship in a larger, representative sample of prostate cancer
patients including information on disease stage.Conclusion
The mGPS is an objective prognostic marker for survival
in prostate cancer patients and has additional value to
other conventional, routinely available information. Pro-
spective studies are required to validate our results and
to test the clinical utility of mGPS in the clinical man-
agement of prostate cancer.
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